Antibodies News and Research

RSS

Prior T cell immunity to SARS-CoV-2 unlikely to be the result of seasonal coronavirus infection

Scientists have suggested that a proportion of the population have pre-existing immunity to COVID-19 because of T cells primed against SARS-CoV-2 antigens.

14 Dec 2020

D614G mutation promotes lysosomal trafficking of SARS-CoV-2 spike protein

In the current COVID-19 pandemic, SARS-CoV-2 has led to millions of infections worldwide, with over 1.5 million deaths.

14 Dec 2020

Recovered COVID-19 patients exhibit persistent cellular immunity

Researchers at The Rockefeller University in New York have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – triggers persistent T cell responses that last for at least six months.

14 Dec 2020

£453,000 grant awarded to boost research and development for COVID-19 antibodies

Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, and Queen’s University Belfast, leader in innovation and impact, have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts.

14 Dec 2020

Pre-existing immunity shapes a person's antibody response to influenza viruses

New research by scientists at the University of Chicago suggests a person's antibody response to influenza viruses is dramatically shaped by their pre-existing immunity, and that the quality of this response differs in individuals who are vaccinated or naturally infected.

11 Dec 2020

Distant residues modulate the conformational opening in SARS-CoV-2 spike protein

Scientists present an insight into the RBD dynamics with physically distant residues in the spike protein, elaborating on the importance of predicted mutations for therapeutics.

11 Dec 2020

New analysis method could pave the way for important breakthroughs in immunotherapy

In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.

11 Dec 2020

Researchers find new method for safe and effective delivery of medicines to the lungs

Investigators at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School recently identified a new method for safe and effective delivery of medicines to the lungs that can be used for multiple clinical applications, potentially including aerosol vaccination.

10 Dec 2020

SARS-CoV-2 infection in pets in COVID-19 positive households: A case study

Researchers tested cats and dogs living in households with COVID-19 positive owners in Texas, US. They found that the pets were also infected in more than 25% of households with a positive case.

10 Dec 2020

Single N primer sufficient for SARS-CoV-2 molecular diagnosis

There is a huge and growing demand for better molecular diagnostic tests for COVID-19, as the pandemic shows few signs of coming under control.

10 Dec 2020

Researchers develop new serological assay for detection of SARS-CoV-2 antibodies

Researchers at UC Santa Cruz have developed a novel serological assay for the detection of antibodies to SARS-CoV-2, the coronavirus that causes COVID-19.

10 Dec 2020

New technology allows rapid detection of specific airborne viruses in the field

Researchers in South Korea have developed a technology that enables immediate detection of specific airborne viruses in the field.

10 Dec 2020

EKF launches high performance quantitative COVID-SeroKlir antibody test kit

EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.

From EKF Diagnostics 10 Dec 2020

Risk of COVID infection in health care workers is driven by community exposure

Nurses only group with higher risk once community exposure considered. Largest cohort of health care worker risk for SARS CoV-2. Only high-flow oxygen therapy and hemodialysis linked to more antibodies to SARS-CoV-2.

10 Dec 2020

Study suggests vast majority of Seattle population remains susceptible to COVID-19

Researchers in the United States have conducted a study suggesting that a small proportion of people living in Seattle were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – by around late March/early April 2020.

9 Dec 2020

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

A recent study by US researchers, currently available on the medRxiv preprint server, evaluated several cell-based assays that are under validation for determining correlates of protection in individuals with symptomatic coronavirus disease (COVID-19) and vaccine studies – and demonstrated their high concordance with both live and pseudotyped virions.

9 Dec 2020

Evolutionary gene mutation unique to humans may be to blame for risk of advanced cancers

Compared to chimpanzees, our closest evolutionary cousins, humans are particularly prone to developing advanced carcinomas -- the type of tumors that include prostate, breast, lung and colorectal cancers -- even in the absence of known risk factors, such as genetic predisposition or tobacco use.

9 Dec 2020

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

Despite the encouraging news of potentially successful COVID-19 vaccine trials, there is not yet an FDA-approved vaccine available. Research into other effective coronavirus vaccines continues, including at UC Davis Health.

8 Dec 2020

High-performing multi-immunoassay for early diagnosis and prognosis of COVID-19

A new study published on the preprint server bioRxiv in December 2020 indicates the ability of anti-SARS-CoV-2 antibody titers and time of induction to differentiate between severe and mild COVID-19 and could lead to the development of a prognostic biomarker for use early in the course of the illness.

8 Dec 2020

Research shows how targeted microbubbles can carry powerful cancer drugs

New research has shown how microbubbles carrying powerful cancer drugs can be guided to the site of a tumor using antibodies.

8 Dec 2020

Antibodies News and Research

Prior T cell immunity to SARS-CoV-2 unlikely to be the result of seasonal coronavirus infection

D614G mutation promotes lysosomal trafficking of SARS-CoV-2 spike protein

Recovered COVID-19 patients exhibit persistent cellular immunity

£453,000 grant awarded to boost research and development for COVID-19 antibodies

Pre-existing immunity shapes a person's antibody response to influenza viruses

Distant residues modulate the conformational opening in SARS-CoV-2 spike protein

New analysis method could pave the way for important breakthroughs in immunotherapy

Researchers find new method for safe and effective delivery of medicines to the lungs

SARS-CoV-2 infection in pets in COVID-19 positive households: A case study

Single N primer sufficient for SARS-CoV-2 molecular diagnosis

Researchers develop new serological assay for detection of SARS-CoV-2 antibodies

New technology allows rapid detection of specific airborne viruses in the field

EKF launches high performance quantitative COVID-SeroKlir antibody test kit

Risk of COVID infection in health care workers is driven by community exposure

Study suggests vast majority of Seattle population remains susceptible to COVID-19

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

Evolutionary gene mutation unique to humans may be to blame for risk of advanced cancers

UC Davis Health joins with Novavax to test a new experimental coronavirus vaccine

High-performing multi-immunoassay for early diagnosis and prognosis of COVID-19

Research shows how targeted microbubbles can carry powerful cancer drugs

Antibodies eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News